Skip to content

Study on Abnormal Savda Munzip Granula treat malignant tumor with depression with Abnormal Savda Syndrome based on proteomics and metabonomics

The folk medicine of combining disease withsyndrome and clinical research of charateristic treatment technology

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16007933
Enrollment
Unknown
Registered
2016-02-16
Start date
2016-02-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor with depression

Interventions

ASMq treatment group:take ASMq for 63 days
Conrtol group:no

Sponsors

Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years, Conforming to malignant tumor diagnostic criteria, and with clear pathology diagnosed; 2. According with affective disorder of Chinese nerve disease classification and diagnostic criteria for the third edition(CCMD-3); 3. HAMD rating scale is more than or equal to eight pointsand SDS rating scale is between 50-70 points; 4. Comfort to Urgur Abnormal savda syndrome; 5. Complete relevant operation, radiotherapy, chemotherapy, intervention therapy 2 weeks before entering the group in line with disease treatment principle; 6. KPS score >= 60; 7. Expected survival for more than 6 months; 8. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients without pathological diagnosed; 2. Not meet Urgur Abnormal savda syndrome; 3. Patients with cardiovascular and cerebrovascular diseases or serious mental disorders and other similar diseases, or patients with combined active tuberculosis and severe infectious diseases; 4. Patients with severe liver or kidney dysfunctionor patients with severe bleeding tendency; 5. Age under 18 or beyond 70 years; 6. Pregnant or lactating women; 7. Allergy to drugs used in this study; 8. Poor nutrition, KPS score < 60; 9. Also received other antineoplastic therapy.

Design outcomes

Primary

MeasureTime frame
Proteomics index;metabonomics;

Countries

China

Contacts

Public ContactHalmurat Upur
wangdm002@163.com+86 0991 4366176

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026